European journal of dermatology : EJD · 2012
Human β-defensin-2 and psoriasin, two new innate immunity targets of zinc gluconate.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Poiraud Carole, Quereux Gaëlle, Knol Anne-Chantal, Zuliani Thomas, Allix Rémy, Khammari Amir, Dreno Brigitte
Аннотация
BACKGROUND: Antimicrobial peptides (AMPs) are a large family of peptides implicated in innate immunity, especially in the epidermis. Zinc gluconate has been proven to be efficient to treat inflammatory dermatoses, such as acne vulgaris.
OBJECTIVES: The aim of our work was to determine whether AMPs could be new targets of zinc gluconate treatment in inflammatory dermatoses.
MATERIAL AND METHODS: To test this hypothesis, we used an ex vivo lipopolysaccharide (LPS)-induced inflammatory skin explant model, with or without zinc gluconate pretreatment. We evaluated human β-defensin-2 (hBD-2), human β-defensin-4 (hBD-4) and psoriasin protein expression and release by immunohistochemistry and ELISA, as well as the mRNA expression level by quantitative PCR.
RESULTS: We found that hBD-2 and psoriasin mRNA expression levels and hBD-2 extracellular release, but not hBD-4 expression and release, were significantly upregulated by zinc gluconate in LPS-stimulated inflammatory skin explants.
CONCLUSION: These results suggest that hBD-2 and psoriasin may be two main targets of zinc gluconate, involved in its anti-inflammatory activity in dermatoses.
OBJECTIVES: The aim of our work was to determine whether AMPs could be new targets of zinc gluconate treatment in inflammatory dermatoses.
MATERIAL AND METHODS: To test this hypothesis, we used an ex vivo lipopolysaccharide (LPS)-induced inflammatory skin explant model, with or without zinc gluconate pretreatment. We evaluated human β-defensin-2 (hBD-2), human β-defensin-4 (hBD-4) and psoriasin protein expression and release by immunohistochemistry and ELISA, as well as the mRNA expression level by quantitative PCR.
RESULTS: We found that hBD-2 and psoriasin mRNA expression levels and hBD-2 extracellular release, but not hBD-4 expression and release, were significantly upregulated by zinc gluconate in LPS-stimulated inflammatory skin explants.
CONCLUSION: These results suggest that hBD-2 and psoriasin may be two main targets of zinc gluconate, involved in its anti-inflammatory activity in dermatoses.